Angiostrongyliasis due to A. cantonensis: first evidence in French West Indies and an up-date in the French overseas territories

C. Dard¹, D. Nguyen², C. Miossec², E. Tessier², K. de Meuron², D. Harrois³, D. Mattera³, L. Epelboin⁴, M. Demar⁴, D. Blanchet⁴, N. Elenga⁴, A. Defo⁴, M. Nicolas⁵, P. Desprez⁵, L. Rulquin⁵, S. Tournier⁵, L. Aubert⁶, N. Traversier⁷, M.C. Jaffar Bandjee⁷, O. Belmonte⁷, G. Miltgen⁷, L. Collet⁸, R. Blondé⁸, A. Chamouine⁸, T. Benoit-Cattin⁸, C. Olivier⁸, M. Giard⁹, A. Guerin¹⁰, F. Ghawche¹⁰, J. Pasche¹⁰, E. Oehler¹⁰, G. Delvallez¹¹, A.C. Gourinat¹¹, S. Lastère¹¹, N. Desbois-Nogard²

¹ CHU Grenoble Alpes, Grenoble, France; ² CHU de la Martinique, Fort-de-France, Martinique, France; ³ CH de Basse-Terre, Basse-Terre, Basse-Terre, Guadeloupe, France; ⁴ CH Andrée Rosemon, Cayenne, Guadeloupe, France; ⁵ CHU de Pointe-à-Pitre, Guadeloupe, France; ⁶ Santé Publique France; Guadeloupe, France; ⁷ CHU Félix-Guyon, Guyane france; ⁸ CHU de Pointe-à-Pitre, Guadeloupe, France; ⁹ CHU de Pointe-à-Pitre, Guadeloupe, France; Saint-Denis, La Réunion, France; 8 CH de Mamoudzou, Mamouzdou, Mayotte, France; 9 Bureau de Veille Sanitaire, Direction de la Santé, Polynésie française, France; 10 CH de Polynésie française, France; 10 CH de Polynésie française, France; 10 CH de Polynésie française, Papeete, Tahiti, France; 11 CH Territorial de Nouvelle-Calédonie, Nouméa, Nouvelle-Calédonie, France; France; 10 CH de Polynésie française, Papeete, Tahiti, France; 11 CH Territorial de Nouvelle-Calédonie, Nouméa, Nouvelle-Calédonie, France; 12 CH de Polynésie française, Papeete, Tahiti, France; 13 CH de Polynésie française, Papeete, Tahiti, France; 14 CH de Polynésie française, Papeete, Tahiti, France; 15 CH de Polynésie française, Papeete, Tahiti, France; 16 CH de Polynésie française, Papeete, Tahiti, France; 18 CH de Polynésie française, Papeete, Tahiti, France; 19 CH de Polynésie française, Papeete, Papeet

Introduction

Angiostrongylus cantonensis

- A. cantonensis: nematode of rat pulmonary arteries
- Leading infectious cause of eosinophilic meningitis in humans

Human angiostrongyliasis (HA)

• Commonly a self-limited meningitis syndrome

• Large spectrum of symptoms possible: asymptomatic disease, mild headache, encephalitis, radiculomyelitis, meningoencephalitis with permanent neurological injury or even death

Life cycle of A. cantonensis (Figure 1)




Figure 1. Life cycle of A. cantonensis.

Rats are definitive hosts. Intermediate hosts (snails and slugs) swallow 1st stage larvae excreted in rats feces. Humans become infected through food containing 3rd stage larvae. Food items may include uncooked snails or slugs vegetables contaminated with snails, slugs, or mollusc secretions (slime), or infected paratenic hosts (i.e., crabs, freshwater shrimp).

Geographic distribution: (Figure 2)

- Most human cases: Southeast Asia, Pacific Basin
- Also possible in some limited parts of Africa and both American continents
- In the Greater Antilles: recent emergence in Cuba, Dominican Republic, Jamaica
- In South America: recent emergence in Brazil and Ecuador In French Territories of the Americas (Guadeloupe, Martinique) and French Guiana): no human cases documented so far




Figure 2. Geographic distribution of angiostrongyliasis human cases worldwide. Adapted from Wang et al., Lancet Infectious diseases, 2008

→ French overseas territories included in the study

Results

Objectives

- ✓ Report the first cases of human angiostrongyliasis (HA) in the French Territories of the Americas (Guadeloupe, Martinique, French Guiana) & perform an investigation of the environmental presence of A. cantonensis in these territories.
- ✓ Provide an update of this disease in all French overseas territories (French Polynesia, New Caledonia, Mayotte Island, La Réunion Island)



Material & Methods

Between 1999 and 2017, all cases of eosinophilic meningitis in French Antilles and French Guiana were investigated using real-time-PCR of CSF or by detection of specific antibodies in sera and CSF. Descriptive analysis was conducted for clinical, biological and radiological features.

Concurrently, cases of HA already diagnosed in French Polynesia, New Caledonia, Mayotte Island and Reunion Island were retrospectively included in the study as far as the medical charts were available. Descriptive analysis was made for clinical, biological, radiological features and risk behavior related to each territory. Results are found in *Table 1*.

Concurrently, 440 mollusks of 9 species (mainly Achatina fulica snails) were collected between 2014 and 2017 at different locations and periods and analyzed for carriage of parasites using realtime-PCR. Preliminary results are found in *Table 2*.

1. Clinical study

| T. Cillical Stady | | _ | | | | | | |
|---|--|--|---|---|--|--------------------------------|--|--|
| | French West Indies | | South America | India | Indian Ocean | | Pacific Basin | |
| | Guadeloupe Island ^a | Martinique Island | French Guiana ^b | Mayotte Island ^c | La Réunion Island ^d | New Caledonia | French Polynesia ^e | |
| Year of first human case | 1999 | 2002 | 2017 | 1996 | 1969 | 1951 | 1961 | |
| Number of reported cases before our study [period, years] | 0 | 0 | 0 | 23 [1996 – 2012] | 8 [1969 – 1998] | 72 [1951 – 2008] | 303 [1961 – 2012] | |
| Cases reported during our study [period, years] | 4 [1999 – 2017] | 8 [2002 – 2017] | 1 [2017] | 7 [2013 – 2017] | 0 (1 from Mayotte) [2017] | 11 [2009 – 2017] | 37 [2012 - 2017] | |
| Mean annual incidence (case/ year) | 0.22 | 0.47 | 1 | 1.4 | 0.1 | 1.3 | 7.4 | |
| Demographic characteristics | | | | | | | | |
| Age (years) | 2.2 [0.6 – 5.0] | 24.3 [0.87 – 63.6] | 10 [10 – 10] | 1 [0.5 – 75] | 3.5 [0.83 – 50] | 36 [0.2 – 73] | 29.5 [3 – 67]* | |
| Sex (male) | 25% | 75% | 100% | 76.2% | 100% | 54.5% | 43.8%* | |
| Exposure risk (contact with snails, shrimps, mental disorders) | 100% | 62.5% | 100% | 58.3% | 100% | 100% | 92.3%* | |
| Main mode of transmission | A. fulica (snails) | A. fulica (snails) | A. fulica (snails) | A. fulica (snails) | ND | A. fulica (snails) | Raw shrimps, « Chevrettes » (Taioro, Mitihue) | |
| Clinical presentation | | | | | | | | |
| Meningeal syndrom | 100% | 100% | 100% | 23.5% | 25% | 0% | 18.8%* | |
| Focal neurological deficit | 50% | 87.5% | 100% | 88.2% | 62.5% | 72.7% | 37.5%* | |
| Laboratory tests | | | | | | | | |
| Total WBC count (G/L) | 14.1 [12.1 – 16] | 10.0 [6.61 – 20.75] | 12.3 [12.3 – 12.3] | ND | 18.5 [11.3 – 24.0] | ND | ND | |
| Eosinophilic count in blood (G/L) (% of WBC) | 2.6 [2.3 – 3.6] (18.5% [17 – 25.5]) | 1.72 [0.49 – 6.43] (12.5% [5 – 31]) | 5.49 [5.49 – 5.49] (44.6% [44.6 – 44.6]) | 2.5 [0.1 – 8.4] (15.9% [1.0 – 33.3]) | 2.8 [1.7 – 5.4] (15.0% [15.0 – 22.0]) | 1.0 [0.0 – 3.1] | 0.9 [0.1 – 2.9]* | |
| WBC count in CSF | 715 [190 – 3000] | 505 [0 – 2280] | 550 [550 – 550] | ND | 1125 [300 – 1700] | 260 [70 – 1100] | 600 [1 – 1000]* | |
| Eosinophilic count in CSF (/mm³) (% of WBC) | 555 [84 – 2040] (56.5% [30 – 89]) | 74.5 [0 – 1550] (25.0% [4 – 68]) | 506 [506 – 506] (92% [92 – 92]) | 193 [3 – 690] (45% [5 – 76]) | 374 [0 - 1275] (47% [34 - 75]) | 70 [7 – 608] (21% [8 – 75]) | 161 [0 – 670]* 38% [0 – 67]) | |
| Glycorachia (mmol/L) | 1.3 [0.91 – 2.8] | 2.81 [0.1 – 4.3] | 4.2 [4.2 – 4.2] | 2.3 [1.1 – 3.5] | 2.2 [1.9 – 7.0] | 2.13 [0.54 – 6.32] | 2.22 [1.28 – 3.72]* | |
| Proteinorachia (g/L) | 0.66 [0.21 – 1.1] | 1.14 [0.33 – 1.71] | 0.43 [0.43 – 0.43] | 0.73 [0.22 – 1.69] | 0.6 [0.3 – 0.65] | 0.89 [0.6 – 5.96] | 0.86 [0.22 – 3.35]* | |
| Positive A. cantonensis PCR in CSF | 100% | ND | 100% | 87.5% | ND | 100% | 62.5%* | |
| Positive A. cantonensis serology in sera | 100% | 87.5% | 100% | ND | 100% | 100% | ND | |
| Detection of A. cantonensis antibodies in CSF | ND | 100% | ND | ND | 100% | 100% | 100%* | |
| Management | | | | | | | | |
| Length of hospital stay (days) | 20.5 [10 – 35] | 27 [15 – 66] | 38 [38 – 38] | ND | 17.5 [17 – 18] | 10 [7 – 150] | 4.5 [1 – 10]* | |
| Corticosteroids | 100% | 62.5% | 100% | 70.6% | 40% | 44.4% | 56.3%* | |
| Anthelmintic therapy (albendazole or ivermectin) | 100% | 87.5% | 100% | 88.2% | 80% | 55.6% | 0%* | |
| Outcome | | | | | | | | |
| Neurological sequelae (%) | 25% | 62.5% | 0% | 15% | 0% | 18.2% | 25% | |
| Death (%) | 0% | 12.5% | 0% | 25% | 20% | 0% | 0% | |

Descriptive results are presented as n (%) and as median [min-max].

*Only the cases occurring in 2017 were statistically analyzed from French Polynesia. ND: not determined

Defo A *et al.,* EID. 2018;

^a Dard C *et al.,* AJTMH. 2017 ;

Epelboin L et al., PNTD. 2016; d Edmar A *et al*, Méd Mal Infect. 1999. / Graber D *et al.,* Arch pédiatr. 1997. / Petithory J et al., Bull Soc Pat Ex, 1977 / Badiaga S et al., Bull Soc Pat Ex, 1993 / Picot H et

al., Acta Tropica, 1975; e Oehler E et al., Parasitol Int, 2014

Table 1. Clinical presentation of the cases along with the biological, imaging and epidemiological features.

2. Environmental survey

| | South America | | | |
|------------------------|---|---|--|--|
| Gı | uadeloupe Island | Martinique Island | French Guiana | |
| 34 | 105 | 135 | 166 | |
| 1 | 1 | 9 | 3 | |
| 11 (32.4%) (Fig. 4) | Currently being analysed (some snails are positive) | Currently being analyzed | Currently being analysed (some snails are positive) | |
| | 34 1 11 (32.4%) | Guadeloupe Island 34 105 1 1 11 (32.4%) Currently being analysed | 34 105 135 1 1 9 11 (32.4%) Currently being analysed Currently being | |

Table 2. First results of environmental evaluation. The evaluation of the prevalence of A. cantonensis in the local mollusk population of French Territories of America is currently underway.

Figure 3. A. A. fulica snail collected in Martinique in June 2017. B. Overview of a part of molluscs collected in Martinique.

Consommation de TAIORO

En cause, l'utilisation de chevrettes crues pour faire fermenter le coco râp

CONGELER les chevrettes au moins 48 heures avant de les utiliser

NE PAS CONSOMMER du TAIORO fait avec

ngite à éosinophile », suite à la consommation de TAIORO.

. cantonensis infected snails Non-infected snails

Figure 4. A geographical map of Guadeloupe showing the distribution of the first snails collected for environmental investigation in 2014 in Basse-Terre and Trois-Rivières cities. Among 34 A. fulica snails collected, 11 (32.4%) were positive by A. cantonensis by PCR. (Dard C. et al. AJTMH. 2017)

Discussion & Conclusion

This study:

• Reports for the first time of human angiostrongyliasis and environmental presence of A. cantonensis in Guadeloupe, Martinique & French Guiana: real emergence in the French Territories of America

- Presents an up-to-date analysis of HA cases in the others French Overseas Territories:
 - > angiostrongyliasis is still a major public health problem in Indian Ocean and Pacific Basin
 - > the incidence of the disease is strongly increasing in French Polynesia

Angiostrongyliasis disease in French overseas Territories

- Risk factors:
 - > children playing in soil and with snails adults with PICA syndrome and mental disorders; consumption of Taioro and Mitihu (raw shrimps & chevrettes) in
 - French Polynesia
- Still a life threatening disease: sequelae from 0 to 62.5%, mortality from 0 to 25%

Angiostrongyliasis, an emerging public health problem?

Territories, particularly in the Pacific Basin

- A. fulica is one of the most invasive mollusc species worlwide, particularly in the Americas
- Misknowledge of the disease: probably underestimate prevalence in all French overseas Territories • Clinicians should strongly consider angiostrongyliasis when determining the causes of eosinophilic meningitis in the French Overseas

Thanks to Max Sibille & Martin Peju for the pictures.

Figure 5. Prevention methods consist in (A) limiting

exposure to snails and snails slime (B) avoiding the

consumption of uncooked freshwater shrimps (i.e.

chevrettes). Picture B is an alert displayed in

supermarkets in Tahiti Island to prevent

angiostrongyliasis meningitis.

Where can A. cantonensis PCR or serology be performed?

PCR. Pasteur Institute of Guadeloupe; CH de Polynésie française, Papeete, Tahiti; CH de Mamoudzou, Mayotte, France; CH Territorial de Nouvelle-Calédonie, Nouméa, France; CDC laboratory, Atlanta, USA

Serology. Swiss Tropical and Public Health Institute, Basel, Switzerland

Acknowledgments

